Koremasa Hayama
Itabashi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications
Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.
Journal: Nature medicine
Published: May 28, 2026
Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II.
Journal: Dermatology and therapy
Published: February 15, 2026
Randomized phase 2a study of TAS5315, a Bruton's tyrosine kinase inhibitor, for chronic spontaneous urticaria.
Journal: Allergology international : official journal of the Japanese Society of Allergology
Published: February 12, 2026
GW240925 and GW250207: Astrophysical Calibration of Gravitational Wave Detectors.
Journal: Physical review letters
Published: January 27, 2026
Comparison of Severity Assessment Methods in Generalized Pustular Psoriasis: A Single-Center Study.
Journal: The Journal of dermatology
Published: January 05, 2026
Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52 Weeks.
Journal: Dermatology and therapy
Published: November 04, 2025
Treatment Guidance for Palmoplantar Pustulosis 2022.
Journal: The Journal of dermatology
Published: November 04, 2025
Response to comments on "Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab".
Journal: The World Allergy Organization journal
Published: October 20, 2025
Last Updated: 09/26/2026